Edison Investment Research - Trimel Pharmaceuticals (TRL) QuickView: A closer look at Tefina Phase II FOD results

Report

Edison Investment Research

QuickView: A closer look at Tefina Phase II FOD results

While Trimel continues to work on securing a commercial licensing transaction for its recently approved Natesto testosterone nasal gel, the firm recently provided further encouraging data on its 253-patient Phase II study for Tefina in female orgasmic disorder (FOD). Trimel continues to analyse the data and plans to meet with the FDA in H214, ahead of the next clinical study.

16/07/2014 2 EN

Underlying

Trimel Pharmaceuticals

See profile

Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Edison Investment Research

QuickView: Endo launches Natesto

US partner Endo has launched Trimelâ€™s Natesto in the c US$2bn US testosterone replacement therapy (TRT) market. Natesto is being positioned as the first and only nasal gel for hypogonadism, and is highlighted for its lower associated risk of testosterone transference.

March 20, 2015 March 20, 2015 2 EN

Edison Investment Research

QuickView: Endo to partner Natesto

Trimel is partnering its Natesto intranasal gel testosterone replacement therapy (TRT) product in the US and Mexico with Endo Pharmaceuticals, receiving US$25m upfront and a tiered supply price for manufacturing. Endoâ€™s marketed portfolio of TRT products makes it an ideal partner, and Trimel expects to be ready for commercial manufacturing in Q115.

December 1, 2014 December 1, 2014 2 EN

Edison Investment Research

QuickView: TRT under FDA spotlight

A joint panel of two FDA advisory committees voted in September to modify the labelling of TRT products to curtail usage when clinical benefit may not be definitive. While it is unclear how the FDA will respond, we believe that end-user demand for TRT will largely persist and that Natestoâ€™s novel delivery should generate interest when launched in H115.

October 17, 2014 October 17, 2014 2 EN

Manx Financial Group - Termination of coverage

Edison Investment Research is terminating coverage on Manx Financial Group (MFX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 10, 2025 March 10, 2025 1 EN

Kate Heseltine

Kate Heseltine

musicMagpie - Termination of coverage

Edison Investment Research is terminating coverage on musicMagpie (MMAG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 5, 2025 March 5, 2025 1 EN

Kate Heseltine

Kate Heseltine

Topps Tiles - Accelerating growth through Q125

Topps Tiles (TPT) is enjoying a return to revenue growth following a very challenging FY24 due to wider macroeconomic weakness. The company’s recovery is clearly being boosted by new revenue streams from its self-help initiatives, notably from trade and online customers across all of its brands. While the macroeconomic environment remains uncertain, it is pleasing that the strategy is supporting growth. The valuation continues to look compelling, even with limited macroeconomic recovery included in management’s long-term financial goals. With the Q125 trading update, the CEO has announced his ...

January 10, 2025 January 10, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QuickView: A closer look at Tefina Phase II FOD results

QuickView: Endo launches Natesto

QuickView: Endo to partner Natesto

QuickView: TRT under FDA spotlight

Manx Financial Group - Termination of coverage

musicMagpie - Termination of coverage

Topps Tiles - Accelerating growth through Q125

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe